ACE2 and infection: While nasal administration of albumin-fused ACE2 is motivated by delivery at the primary site of infection, combined with the ability to engage FcRn for half-life extension and transmucosal transport to local tissues and blood (76), bioencapsulation may not be required to withstand the acidic and enzymatic conditions within the gastrointestinal tract.